Hepatitis B virus reactivation in inflammatory bowel diseases
Kanmura, S.; Moriuchi, A.; Hamamoto, H.; Ido, A.
Nihon Rinsho. Japanese Journal of Clinical Medicine 75(3): 461-465
2017
ISSN/ISBN: 0047-1852 PMID: 30566792 Document Number: 694762
Immunosuppressive therapy is a standard treatment for inflammatory bowel disease. However, immunosuppressive therapy is associated with severe side effects such as serious infection. In particular, hepatitis B virus (HBV) reactivation is a concern because it often leads to severe or fatal hepatitis. Screening for HBV infection using the the Japan Society of Hepatology guidelines for the management of Hepatitis B Virus infection published by the drafting committee prior to immunosuppressive therapy or chemother- apy is recommended. Observing the guidelines can prevent severe hepatitis.